Industry news

31 May 2018

Clearside Biomedical Announces Positive Topline Results from Phase 2 Clinical Trial of CLS-TA Used with Eylea in Patients with Diabetic Macular Edema

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced positive topline results from its Phase 2 clinical trial (“TYBEE”) evaluating suprachoroidal CLS-TA used with intravitreally administered EYLEA® (aflibercept) (“intravitreal Eylea”) in patients with diabetic macular edema (“DME”) over a 6-month evaluation period.

Best Particle Therapy will introduce a revolutionary cancer treatment

GMP News

Best Theratronics Ltd. (BTL), Best Cyclotron Systems (BCS), Best Particle Therapy (BPT), and Best Medical International (BMI) – all part of TeamBest Medical Companies – are the only companies offering a range of new medical cyclotrons and synchrotrons. These use the most advanced new technologies to offer revolutionary diagnosis and treatment capabilities.

30 May 2018

Syndax and Nektar Therapeutics Announce Immuno-Oncology Clinical Trial Collaboration

Syndax Pharmaceuticals, Inc.  ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the first quarter ended  March 31, 2018 . In addition, the Company provided a clinical and business update. As of  March 31, 2018 , Syndax had  $113.2 million  in cash, cash equivalents and short-term investments.

Russia has one of shortest periods for introducing foreign drugs onto the market

GMP News

The recognition of foreign drug certificates in Russia should be based on the principles of reciprocity. This was announced by Elena Maksimkina, the Head of the Department of Drug Supply and Regulation of Medical Devices at the Ministry of Health of the Russian Federation, who spoke on May 26 on the sidelines of the St. Petersburg International Economic Forum.

Russian Ministry of Industry and Trade wants to support Russian pharma R&D

GMP News

Pharma-2020 Program provides for the establishment of a venture capital fund to support R&D of Russian pharmaceutical companies at the early stages, announced Alexey Alekhin, the Head of Department of Pharmaceutical and Medical Industry Development of the Russian Ministry of Industry and Trade, at the 2018 St. Petersburg International Economic Forum.

Russia will have its first quadrivalent influenza vaccine

GMP News

In the near future, Russia will register its first locally-produced quadrivalent influenza vaccine. According to the experts, this vaccine has not only the most effective and safe profile possible today, but also provides undeniable pharmacoeconomic advantages. Its use will allow to prevent up to 265.8 thousand cases of influenza per season and save more than 2.5 billion rubles of state budget funds compared to traditional trivalent vaccines.

Up-and-coming Pfizer, AbbVie drugs set to threaten Amgen, Celgene: analyst

Carly Helfand / FiercePharma

With Pfizer’s Xeljanz snapping up new indications and AbbVie’s upadacitinib on the way, makers of anti-inflammatory drugs will soon feel the heat from JAK inhibitors if they haven't already. But some will feel it more than others, Bernstein analysts say.

API market is expected to attain a valuation of $219,601.9 by the end of 2023

GMP News

For the manufacturers of drugs, active pharmaceutical ingredients (APIs) are of great essence as their quality defines the effectiveness of the products. However, not all pharmaceutical companies possess in-house API manufacturing capabilities and it is not feasible for a single company to produce all the APIs required for their formulation offerings. The report of Transparency Market Research agency provides detailed qualitative analysis of the market dynamics that affect the growth of the global market.

Bayer plans to increase the share of its localized products in Russia

GMP News

In the next 3-5 years, Bayer intends to raise the share of its localized products in Russia to 30% of the total sales of the company. The company is already implementing a number of large-scale projects to localize the manufacturing of innovative medicines, said Nils Hessmann, General Representative of Bayer in Russia and CIS.

24 May 2018

Evofem Biosciences Announces Closing of Public Offering of Common Stock and Warrants

Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, today announced the closing of its previously announced underwritten public offering of 8.5 million shares of common stock or, in lieu of shares of common stock, pre-funded warrants exercisable for shares of common stock, and accompanying common warrants to purchase an aggregate of 1.7 million shares of common stock. At closing, Evofem received net proceeds from the offering of approximately $36.4 million, after deducting offering expenses. All of the securities in the offering were sold by Evofem.